




Community Cancer Program 2023 Annual Report



STATISTICAL DATA FROM 2022

STATISTICAL SUMMARY of CANCER CASES at CALVERTHEALTH MEDICAL CENTER

Calendar Year 2023 Statistics (January 1-December 31, 2022)

Patient Demographics

In 2022, there were 382 new cancer cases accessioned at CalvertHealth. Of the 382 new cancer cases, 348 were analytical cases and 34 were non-analytical cases. Analytic cases are those diagnosed at our hospital, or who received all or part of their initial course of treatment here. Non-analytical cases were seen for recurrent or progressive diseases.

Managed Care/HMO/PPO was the primary insurance coverage for 41% of the patients, followed by Medicare with Private Supplement 26%, non-insured at 1% and all others (including Medicaid and insurance not specified) at 32%.

Sex distribution shows 33% male and 67% female. Race distribution included: 87% White, 12% Black, 1% other Asian, including Asian, NOS and Oriental, NOS.

Top 5 Sites:

Figure 4 (opposite page) summarizes the top five primary sites for 2022 which includes breast (100 cases), lung (43 cases), prostate (36 cases), urinary bladder (33 cases) and corpus uteri (26 cases).

Figure 1: 2022 Analytic vs Non-Analytic Data




Figure 2: 2022 Gender Distribution at CHMC




Figure 3: 2022 Race Distribution





Figure 4: 2022 Top Five Sites at CHMC



STATISTICAL SUMMARY of CANCER CASES at CALVERTHEALTH MEDICAL CENTER

Calendar Year 2023 Statistics (January 1-December 31, 2022)

Summary of Body System and Sex Report

| DISEASE SITE | MALES | | FEMALES | | TOTAL | |
|------------------------------|-------|-----------|---------|-----------|-------|-----------|
| TOTALS | 155 | (100.00%) | 227 | 100.00% | 382 | 100.00% |
| Lip / Oral Cavity / Pharynx | 5 | (3.23 %) | 0 | (0.00 %) | 5 | (1.31 %) |
| Esophagus | 3 | (1.94 %) | 0 | (0.00 %) | 3 | (0.79 %) |
| Stomach | 0 | (0.00 %) | 1 | (0.44 %) | 1 | (0.26 %) |
| Small Intestine | 1 | (0.65 %) | 0 | (0.00 %) | 1 | (0.26 %) |
| Colon | 10 | (6.45 %) | 8 | (3.52 %) | 18 | (4.71 %) |
| Rectum | 1 | (0.65 %) | 4 | (1.76 %) | 5 | (1.31 %) |
| Anus | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Liver | 2 | (1.29 %) | 3 | (1.32 %) | 5 | (1.31 %) |
| Pancreas | 3 | (1.94 %) | 7 | (3.08 %) | 10 | (2.62 %) |
| Other Digestive Organ | 1 | (0.65 %) | 1 | (0.44 %) | 2 | (0.52 %) |
| Larynx | 2 | (1.29 %) | 0 | (0.00 %) | 2 | (0.52 %) |
| Lung | 19 | (12.26 %) | 24 | (10.57 %) | 43 | (11.26 %) |
| Other Respiratory | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Bones and Joints | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Soft Tissue | 0 | (0.00 %) | 2 | (0.88 %) | 2 | (0.52 %) |
| Melanoma - Skin | 2 | (1.29 %) | 2 | (0.88 %) | 4 | (1.05 %) |
| Kaposi Sarcoma | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Mycosis Fungoides | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Other Skin | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Breast - Female | 0 | (0.00 %) | 99 | (43.61 %) | 99 | (25.92 %) |
| Breast - Male | 1 | (0.65 %) | 0 | (0.00 %) | 1 | (0.26 %) |
| Cervix | 0 | (0.00 %) | 7 | (3.08 %) | 7 | (1.83 %) |
| Corpus Uteri | 0 | (0.00 %) | 26 | (11.45 %) | 26 | (6.81 %) |
| Ovary | 0 | (0.00 %) | 4 | (1.76 %) | 4 | (1.05 %) |
| Other Female Genital | 0 | (0.00 %) | 3 | (1.32 %) | 3 | (0.79 %) |
| Prostate | 36 | (23.23 %) | 0 | (0.00 %) | 36 | (9.42 %) |
| Other Male Genital | 1 | (0.65 %) | 0 | (0.00 %) | 1 | (0.26 %) |
| Urinary Bladder | 26 | (16.77 %) | 7 | (3.08 %) | 33 | (8.64 %) |
| Kidney | 1 | (0.65 %) | 1 | (0.44 %) | 2 | (0.52 %) |
| Other Urinary | 0 | (0.00 %) | 3 | (1.32 %) | 3 | (0.79 %) |
| Eye and Orbit | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Brain and Nervous System | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Thyroid | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Other Endocrine System | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Non-Hodgkin Lymphoma | 8 | (5.16 %) | 6 | (2.64 %) | 14 | (3.66 %) |
| Hodgkin Lymphoma | 4 | (2.58 %) | 1 | (0.44 %) | 5 | (1.31 %) |
| Multiple Myeloma | 2 | (1.29 %) | 1 | (0.44 %) | 3 | (0.79 %) |
| Lymphoid Leukemia | 6 | (3.87 %) | 1 | (0.44 %) | 7 | (1.83 %) |
| Myeloid / Monocytic Leukemia | 4 | (2.58 %) | 7 | (3.08 %) | 11 | (2.88 %) |
| Leukemia - Other | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Other Hematopoietic | 5 | (3.23 %) | 2 | (0.88 %) | 7 | (1.83 %) |
| Unknown Sites | 7 | (4.52 %) | 2 | (0.88 %) | 9 | (2.36 %) |
| Ill-Defined Sites | 0 | (0.00 %) | 0 | (0.00 %) | 0 | (0.00 %) |
| Other | 1 | (0.65 %) | 0 | (0.00 %) | 1 | (0.26 %) |
| Benign Brain and CNS | 4 | (2.58 %) | 5 | (2.20 %) | 9 | (2.36 %) |

Exclusions: All non-analytic cases and patients diagnosed at Calvert who received treatment at another facility.